Tasigna in Glivec-resistant or Intolerant Patients in CML

Clinical trial NCT01206088 · COMPLETED

Trial details

NCT number: NCT01206088
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

CML Nilotinib Imatinib Resistant Imatinib Intolerant

Start date: 2009-02-01
Primary completion: 2012-09-01
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.